Advertisement
Advertisement
HIGHLIGHT
Wegovy

Wegovy

semaglutide

Manufacturer:

Novo Nordisk

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Semaglutide
Indications/Uses
Adjunct to reduced-calorie diet & increased physical activity for wt management including wt loss & maintenance in adults w/ initial BMI ≥30 kg/m2 (obesity) or ≥27 to <30 kg/m2 (overwt) in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (prediabetes or type 2 DM), HTN, dyslipidaemia, obstructive sleep apnoea or CV disease.
Dosage/Direction for Use
SC Initially 0.25 mg once wkly (wk 1-4), increased to 0.5 mg once wkly after 4 wk (wk 5-8), then 1 mg once wkly (wk 9-12) & further increased to 1.7 mg once wkly (wk 13-16). Maintenance dose: 2.4 mg once wkly.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Not to be inj IV or IM. Not a substitute for insulin in patients w/ type 2 diabetes. Discontinue use if pancreatitis is suspected & not to be restarted if pancreatitis diagnosis is confirmed. Not recommended in patients w/ type 2 diabetes w/ uncontrolled or potentially unstable diabetic retinopathy; type 1 diabetes; CHF NYHA class IV. Patients w/ inflammatory bowel disease; diabetic gastroparesis; history of pancreatitis. Increased risk of hypoglycaemia in combination w/ sulfonylurea or insulin. Aspiration associated w/ general anaesth or deep sedation. Avoid fluid depletion. Closely monitor patients w/ diabetic retinopathy. Not to be used in combination w/ other GLP-1 receptor agonists. May affect ability to drive & use machines. Not recommended in severe hepatic & renal (eGFR <30 mL/min/1.73 m2) impairment including ESRD. Mild or moderate hepatic impairment. Women of childbearing potential must use effective contraception. Not to be used during pregnancy & lactation. Childn & adolescents <18 yr. Elderly ≥75 yr.
Adverse Reactions
Headache; vomiting, diarrhoea, constipation, nausea, abdominal pain; fatigue. Hypoglycaemia, diabetic retinopathy (patients w/ type 2 diabetes); dizziness, dysgeusia, dysaesthesia; gastritis, GERD, dyspepsia, eructation, flatulence, abdominal distension; cholelithiasis; hair loss; inj site reactions.
Drug Interactions
Decreased INR w/ acenocoumarol. Frequent INR monitoring w/ warfarin or other coumarin derivatives. Concomitant use w/ oral medicinal products requiring rapid GI absorption.
MIMS Class
Anti-Obesity Agents / Antidiabetic Agents
ATC Classification
A10BJ06 - semaglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Wegovy FlexTouch soln for inj (pre-filled pen) 0.25 mg/dose
Packing/Price
(4 doses) 1.5 mL x 1's
Form
Wegovy FlexTouch soln for inj (pre-filled pen) 0.5 mg/dose
Packing/Price
(4 doses) 1.5 mL x 1's
Form
Wegovy FlexTouch soln for inj (pre-filled pen) 1 mg/dose
Packing/Price
(4 doses) 3 mL x 1's
Form
Wegovy FlexTouch soln for inj (pre-filled pen) 1.7 mg/dose
Packing/Price
(4 doses) 3 mL x 1's
Form
Wegovy FlexTouch soln for inj (pre-filled pen) 2.4 mg/dose
Packing/Price
(4 doses) 3 mL x 1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement